文献速递白血病造血干细胞移植与细胞治疗

儿童急性淋巴细胞白血病中的CAR-T细胞治疗:过去、现在与未来

CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
PubMed 文献 · Br J Haematol · 2020-01-01

该综述回顾了CAR-T细胞疗法在儿童复发/难治性B细胞恶性肿瘤中的发展,重点讨论CD19靶向CAR-T产品在儿童B细胞急性淋巴细胞白血病中的获批应用,并梳理短期免疫毒性、反应持久性、可及性及拓展适应症等挑战。

要点

  • CD19靶向CAR-T已获批用于儿童难治、移植后复发或二次及以上复发的B细胞急性淋巴细胞白血病。
  • CAR-T可克服对放化疗抵抗的疾病,也为已达标准治疗毒性上限者提供选择。
  • 短期免疫毒性、反应持久性、可及性和适应症拓展仍是主要挑战。

核心结论

  • CD19靶向CAR-T细胞疗法在儿童B细胞急性淋巴细胞白血病中已确立治疗地位,但仍有待解决的多重挑战以充分发挥其变革性潜力。

研究设计与样本

  • 综述类文章,检索范围未在摘要中报告,聚焦英国血液学会成立60周年背景下本社区对儿童CD19靶向CAR-T治疗成功的贡献。

主要发现

  • 过去十年CAR-T细胞疗法已成为儿童和成人复发/难治性B细胞恶性肿瘤有前景的治疗手段。
  • CD19靶向CAR-T产品已获批用于儿童难治、移植后复发或二次及以上复发的B细胞急性淋巴细胞白血病。

临床怎么用

  • CD19靶向CAR-T可用于儿童难治、移植后复发或二次及以上复发的B细胞急性淋巴细胞白血病。

局限性

  • 摘要未报告综述的检索范围与纳入标准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Over the last decade, chimeric antigen receptor (CAR)-T cell therapy has emerged as a promising treatment modality for relapsed/refractory B-cell malignancies in both children and adults. As an adoptive immune therapy, CAR-T cells have the potential to overcome disease that is resistant to chemo- and radiotherapy as well as represent a viable option for those who have already reached toxicity ceilings with standard therapies. CD19-directed CAR-T cell products have been licensed for use in paediatric B-cell acute lymphoblastic leukaemia that is refractory, in relapse post-transplant or in second or later relapse. Many challenges remain, rightly resulting in a heavily-mined research field. These include mitigating short-term immune-mediated toxicity, maintaining durability of responses, broadening treatment accessibility and extending its applicability to other malignant settings. In this review, dedicated to marking 60 years since the establishment of the British Society for Haematology, we will focus on the contribution of our community towards the success of CD19-directed CAR-T cell therapy in children. We will put current practice in CAR-T cell therapy into the context of future challenges to be addressed in order for it to fulfil its "game-changing" therapeutic potential.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Rogosic S, Ghorashian S. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future. Br J Haematol. 2020. PMID: 33190266. doi:10.1111/bjh.17153

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。